Malignant astrocytomas presenting in humans of any age group are a challenge to diagnose and treat. Hence, there is a quest for new markers to ascertain their grades and predict disease outcomes. Proline, glutamic acid, and leucine-rich protein 1 (PELP1), a nuclear receptor co-regulator, is an oncogene found in various cancers. We postulate that by screening for PELP1, its correlation with survival outcomes of patients across various grades can indicate a plausible novel diagnostic marker and a potential therapeutic target in gliomas. Immunostaining of 100 cases of astrocytomas for PELP1 was performed on paraffin-embedded sections. Results showed that PELP1 expression increases with higher grades; the mean H-score of PELP1 in grade-I astrocytomas was determined to be 112.3, whereas in grade-IV it was 235.1 (P value = 0.0001). Survival analysis of patients with H-score of 200–300 was only 8.8% and 68.8% in patients with scores of 0–100. PELP1 expression in high-grade astrocytomas is an important factor in determining the outcomes.

在任何年龄段的人类中都存在的恶性星形细胞瘤是诊断和治疗的挑战。因此，需要寻找新的标记物以确定其等级并预测疾病的结果。脯氨酸，谷氨酸和富含亮氨酸的蛋白1（PELP1）是一种核受体协同调节剂，是在多种癌症中发现的癌基因。我们推测通过筛选PELP1，其与不同年级患者的生存结果之间的相关性可以表明是合理的新型诊断标记物和神经胶质瘤的潜在治疗靶标。在石蜡包埋的切片上对100例星形细胞瘤的PELP1进行了免疫染色。结果表明，PELP1表达随着等级的升高而增加；在I级星形细胞瘤中，PELP1的平均H分数被确定为112.3，而在IV级星形胶质瘤中，它的平均H分数为235.1（P值= 0.0001）。H评分为200–300的患者的生存分析仅为0–100评分的患者的8.8％和68.8％。PELP1在高度星形细胞瘤中的表达是决定转归的重要因素。